Replication of the INSPIRE Trial in Healthcare Claims Data
NCT05179512 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 98278
Last updated 2023-07-27
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
Tiotropium
Tiotropium dispensing claim is used as the reference group.
- DRUG
-
salmeterol-fluticasone
Salmeterol/Fluticasone dispensing claim is used as the exposure group.
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-22
- Primary Completion
- 2021-08-30
- Completion
- 2021-08-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50
NCT03562923 ·Status: UNKNOWN ·Phase: PHASE3
-
Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02173782 ·Status: COMPLETED ·Phase: PHASE3
-
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
NCT01559116 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
NCT01513460 ·Status: COMPLETED ·Phase: PHASE3
-
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
NCT01760304 ·Status: TERMINATED ·Phase: PHASE4
-
Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients
NCT01921127 ·Status: COMPLETED
-
Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02236182 ·Status: COMPLETED ·Phase: PHASE2
-
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00239421 ·Status: COMPLETED ·Phase: PHASE4
-
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01708057 ·Status: TERMINATED ·Phase: PHASE2
-
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
NCT00400153 ·Status: COMPLETED ·Phase: PHASE3
-
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00239473 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
NCT00421122 ·Status: COMPLETED ·Phase: PHASE3
-
Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients
NCT02969317 ·Status: COMPLETED ·Phase: PHASE1
-
Phase IV O2 Consumption Study in COPD Patients.
NCT02533505 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
NCT00501852 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01574651 ·Status: COMPLETED ·Phase: PHASE3
-
Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT02172794 ·Status: COMPLETED ·Phase: PHASE3
-
Re-usable Respimat® Soft MistTM Inhaler Study
NCT04011735 ·Status: COMPLETED
-
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT01572792 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
NCT00206154 ·Status: COMPLETED ·Phase: PHASE3
-
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
NCT02573155 ·Status: COMPLETED ·Phase: PHASE1
-
A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler
NCT02172560 ·Status: COMPLETED
-
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06035393 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
NCT00530842 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01415518 ·Status: COMPLETED ·Phase: PHASE4